Prospective study of the natural history of gastrinoma in patients with MEN1: Definition of an aggressive and a nonaggressive form

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 11, 2001, Pages 5282-5293

  Gibril, Fathia ^a   Venzon, David J ^b   Ojeaburu, Jeremiah V ^a   Bashir, Showkat ^a   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GASTRINOMA; HUMAN; LIVER METASTASIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; ZOLLINGER ELLISON SYNDROME;

EID: 0035176305     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.11.8011     Document Type: Article

References (64)

1. Clinical studies of multiple endocrine neoplasia type 1 (MEN1)
2. The MEA-I syndrome: An all or none phenomenon?
3. Multiple endocrine neoplasia
4. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands
5. Lethality of multiple endocrine neoplasia type I
6. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
7. Cause of death in multiple endocrine neoplasia type 1
8. Are patients with multiple endocrine neoplasia type I prone to premature death?
9. Multiple endocrine neoplasia type 1: Clinical and genetic topics
10. Familial endocrine adenoma-peptic ulcer disease
11. Enteropancreatic malignancy associated with multiple endocrine neoplasia type 1
12. Multiple endocrine neoplasia type 1: Clinical features and management
13. Survival factors in patients with endocrine liver metastases
14. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome
15. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study
16. Natural history of digestive endocrine tumors
17. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area
18. Benign and malignant gastrinoma
19. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns
20. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management
21. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1
22. Surgery to cure the Zollinger-Ellison syndrome
23. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1
24. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study
25. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: The best approach
26. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome
27. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome
28. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: A prospective study
29. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1
30. Imaging for pancreatic endocrine tumor localization: Recent advances
31. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study
32. Role of surgery in MEN1 patients with gastrinomas advanced disease
33. Surgical treatment of localized gastrinoma within the liver: A prospective study
34. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas
35. Surgical pathology of gastrinoma: Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy
36. Zollinger-Ellison syndrome
37. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: Correlation with primary tumor size
38. The natural history of multiple endocrine neoplasia type I. Highly uncommon or highly unrecognized
39. Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment
40. Multiple endocrine neoplasia type I: A 10-year prospective screening study in four kindreds
41. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias
42. Gastrinoma
43. Gastrinoma: Factors influencing prognosis
44. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients
45. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia
46. Medical and surgical options in the management of patients with gastrinoma
47. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours
48. Pancreatic endocrine tumors
49. Recent advances in the treatment of metastatic pancreatic endocrine tumors
50. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia
51. Management of islet cell tumors in patients with multiple endocrine neoplasia type 1
52. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1
53. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1
54. Thymic carcinoids in multiple endocrine neoplasia type 1
55. Total pancreatectomy in the MEN-1 syndrome
56. Cytoreductive hepatic surgery for metastatic gastrointestinal neuroendocrine tumors
57. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors
58. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma
59. Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment
60. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists
61. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors
62. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
63. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors
64. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: Surgery or surveillance?